# Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children

> **NCT03447782** · PHASE1,PHASE2 · COMPLETED · sponsor: **Boston Children's Hospital** · enrollment: 45 (actual)

## Conditions studied

- New Daily Persistent Headache (NDPH)

## Interventions

- **DRUG:** Naltrexone HCl (Bulk) Powder

## Key facts

- **NCT ID:** NCT03447782
- **Lead sponsor:** Boston Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-23
- **Primary completion:** 2020-11-20
- **Final completion:** 2020-11-20
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2022-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03447782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03447782, "Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03447782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*